Watch for Andexxa, the New Apixaban and Rivaroxaban Reversal Agent
July 2018
You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent.
Andexxa binds and inactivates factor Xa inhibitors...compared to idarucizumab (Praxbind), which reverses dabigatran (Pradaxa).
Andexxa's FDA approval is based on quick reversal of clotting time in patients taking apixaban and rivaroxaban. But it's also being studied with other anticoagulants...betrixaban (Bevyxxa), edoxaban (Savaysa), and enoxaparin.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote